Mice that received this combined treatment exhibited significantly longer survival and smaller tumor sizes (P< 0.01), suggesting that the ACAT1 inhibitor enhances the effect of the CSCs-DC vaccine against postoperative tumor recurrence. This evidence concerns the gene ACAT1 and neoplasm.